• Population ~ 23, 625, 600 (www.abs.gov.au) • Indigenous Australians represent ~3% population TTANGO: Test, Treat ANd GO
Map of remote Australian Communites
Health services in remote Australia 
STIs in remote Australia
• High rates of chlamydia and gonorrhoea in remote Aboriginal communities
• Prevalence of any STI in 16-19 years old (Silver et al. Sex Transm Infect, 2014) -Males 33.4%
-Females 48.9%
CHLAMYDIA

GONORRHOEA
STI management
• Symptomatic infections treated presumptively • Specimens sent to laboratories for testing • Long delays to treatment -3 weeks for asymptomatic patients (Guy et al. Sexual Health, 2012) • Frequent loss to follow-up -up to 20% remain untreated (Guy et al. Sexual Health, 2012) • (Dommelen et al. Sex Transm Infect 2010; Watchirs-Smith et al. Sex Transm Infect, 2013) New molecular-based POC tests
• GeneXpert CT/NG assay (Cepheid)
• Dual organism (CT +NG) detection • Two targets for NG • 90 minutes to result • High analytical sensitivity/specificity (Tabrizi et al. J Clin Micro, 2013) • Excellent performance in pilot field evaluation (Causer et al, Sex Health 2014) • Suited to use at the point-of-care (Peeling. STI, 2011) GeneXpert platform
• Already available and used for Further testing of discordants
• 10/16 discordants investigated further at reference lab* *Royal Womens Hospital (Melbourne): Samples in Cobas transport media/urine retested by Cobas 4800 (for both CT and NG) and by In-house Omp CT assay, In-house PorA and Opa NG assays. Swab or Aptima samples were extracted and run on the inhouse Omp CT assay, In house PorA and Opa NG assays only.
